The global monoclonal antibodies (mAbs) market, valued at USD 186 billion in 2021, is projected to grow at a robust compound annual growth rate (CAGR) of 12% from 2022 to 2032. This growth is driven by the increasing prevalence of chronic diseases such as cancer and cardiovascular conditions, which are boosting the demand for biologics. …